Pasithea Therapeutics Corp
NASDAQ: KTTA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Pasithea Therapeutics Corp (KTTA) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2020 | — | $-61476.00 | — | — | — |
| 2021 | $15062.00 | $-2.17M | -14.69% | -29,925.73% | -14,430.49% |
| 2022 | $486559.00 | $-13.94M | -1.05% | -2,587.35% | -2,864.29% |
| 2023 | $486559.00 | $-15.96M | -133.27% | -3,284.16% | -3,280.52% |
| 2024 | $0.00 | $-13.90M | — | — | — |
| 2025 | $0.00 | $-20.43M | — | — | — |
Frequently asked questions
What is Pasithea Therapeutics Corp's revenue?
Pasithea Therapeutics Corp's trailing twelve-month revenue is $486560.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does KTTA generate?
KTTA produced $-15.21B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is KTTA's balance sheet healthy?
KTTA holds $55.16M in cash and equivalents against — in long-term debt, on $55.22M of shareholder equity. That debt is best read against the cash flow the business throws off each year.